Gene-methylation interactions: Discovering region-wise DNA methylation levels that modify SNP-associated disease risk by Romanowska, Julia et al.





levels thatmodify SNP-associated disease risk
Julia Romanowska1,2,3* , Øystein A. Haaland1, Astanand Jugessur1,3,4, Miriam Gjerdevik1,4, Zongli Xu5,
Jack Taylor5, Allen J. Wilcox5, Inge Jonassen2, Rolv T. Lie1,3 and Håkon K. Gjessing1,3
Abstract
Background: Current technology allows rapid assessment of DNA sequences and methylation levels at a single-site
resolution for hundreds of thousands of sites in the human genome, in thousands of individuals simultaneously. This
has led to an increase in epigenome-wide association studies (EWAS) of complex traits, particularly those that are
poorly explained by previous genome-wide association studies (GWAS). However, the genome and epigenome are
intertwined, e.g., DNA methylation is known to affect gene expression through, for example, genomic imprinting.
There is thus a need to go beyond single-omics data analyses and develop interaction models that allow a
meaningful combination of information from EWAS and GWAS.
Results: We present two newmethods for genetic association analyses that treat offspring DNAmethylation levels as
environmental exposure. Our approach searches for statistical interactions between SNP alleles and DNA methylation
(G×Me) and between parent-of-origin effects and DNA methylation (PoO×Me), using case-parent triads or dyads. We
use summarized methylation levels over nearby genomic region to ease biological interpretation. The methods were
tested on a dataset of parent–offspring dyads, with EWAS data on the offspring. Our results showed that methylation
levels around a SNP can significantly alter the estimated relative risk. Moreover, we show how a control dataset can
identify false positives.
Conclusions: The new methods, G×Me and PoO×Me, integrate DNA methylation in the assessment of genetic
relative risks and thus enable a more comprehensive biological interpretation of genome-wide scans. Moreover, our
strategy of condensing DNA methylation levels within regions helps overcome specific disadvantages of using sparse
chip-based measurements. The methods are implemented in the freely available R package Haplin (https://cran.r-
project.org/package=Haplin), enabling fast scans of multi-omics datasets.
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Background
Genome-wide association studies (GWAS) of single-
nucleotide polymorphisms (SNPs) have contributed enor-
mously to our understanding of the genetic underpinnings
of various complex diseases. However, it has become
increasingly clear that the heritability of a disease cannot
be fully explained by GWAS alone, prompting researchers
to examine rare variants, other types of omics data, and
alternative disease mechanisms in an attempt to explain
themissing heritability.
The term “epigenome” is widely used to encapsulate
all the epigenetic processes involved in regulating gene
expression in the entire genome. Epigenome-wide associ-
ation studies (EWASes) have become a relatively common
complementary omics to GWAS as a result of major
advances in high-throughput microarray-based technolo-
gies for measuring DNA methylation (DNAm) [1, 2].
Among several epigenetic modifications characterized to
date, DNAm is by far the most studied epigenetic mark in
humans. It is a process by which a methyl group binds to
the cytosine (C) at a CpG dinucleotide, resulting in activa-
tion or repression of gene expression throughmechanisms
that are highly region- and context-dependent [3–5]. Fur-
thermore, it has been shown that the state of methylation
is controlled by several enzymes [6] and is influenced by
environmental exposures [7].
A standard GWAS analysis for a dichotomous pheno-
type computes relative risks (RRs) between all SNPs and
the phenotype. However, it is easy to envision that the
effect of a SNP on the phenotype can be modified by
DNAm levels in the nearby regions, for instance, when
DNAm affects the gene expression. In statistical terms,
this corresponds to finding an interaction between the
SNP and nearby CpG methylation levels. For instance,
the RRs may differ depending on whether DNAm lev-
els are low, medium, or high. Here, we refer to this as a
gene–methylation interaction effect (G×Me).
We are aware of only two studies in the literature that
have explored G×Me effects [8, 9]. The authors of those
papers analyzed several SNPs and one CpG in a candidate
gene for asthma and detected a statistically significant
interaction between a specific SNP–CpG pair. The rela-
tive risk of asthma associated with the SNP increased with
an increasing level of methylation at the CpG site. Both
studies were, however, limited in that they only investi-
gated a few SNPs in one gene and only a single CpG, which
were selected a priori because they all showed significant
associations with the phenotype. Developing an efficient
method that could be applied to the entire genome and
epigenome would thus advance the field substantially by
enabling an agnostic search for G×Me interactions.
In addition to G×Me interactions, it is important
to consider parent-of-origin (PoO) effects, which may
account for a fraction of the unexplained heritability of a
trait. Here, we define a PoO effect as the effect of a par-
ticular allele in the child depending on whether the allele
is inherited from the mother or the father; see the refer-
ences and discussion in our previous work [10]. While the
main genetic and gene–environment (G×E) effects can be
estimated using a case–control design, assessing a PoO
effect requires genetic information from at least one par-
ent, thus a dyad or triad design [11]. An advantage of these
family-based designs is that it is possible to estimate G×E
effects even when only the genotypes of the case fami-
lies are available [12]. The ability to estimate PoO effects
opens an entirely unexplored possibility, namely to study
how DNAm levels influence PoO effects. Previously, we
have developed models for estimating PoO×E effects in
GWAS analyses, where E denotes an external environ-
mental exposure [10, 13, 14]. By letting DNAm levels take
the role of the exposure variable, we can thus evaluate
PoO×Me effects, i.e., we can study how the PoO effect
changes depending on the nearby DNAm levels.
While G×Me effects are interpreted analogously to
those derived from a cohort or case–control setting, the
PoO×Me interactions offer an intriguing extension. Since
genetic imprinting can lead to a PoO effect for a pheno-
type association, methylation levels at CpGs located near a
SNP exhibiting a PoO effect may influence the magnitude
of that effect.
In this paper, we treat the level of DNAm as environ-
mental exposure and develop new statistical methods to
estimate G×Me and PoO×Me interactions from case-
parent triads and dyads in a full GWAS-EWAS setting.
Our implementation of the methods is applicable to any
dichotomous trait where genotypes and methylation sta-
tus are available on cases (affected children), and the
genotypes of at least one parent can be obtained. For each
SNP, we investigate DNAm in various genomic regions
and not only at a single CpG site because correlated CpGs
are known to exert their effects over long stretches of
DNA [15–17].
G×E analyses using case-parent triads are generally
robust in the sense that they only require genes and envi-
ronment to be statistically independent, conditional on
parental genotypes [18]. This somewhat technical con-
dition would usually be satisfied when E represents an
external environmental factor. However, replacing E with
Me may be problematic in a few cases, such as when
the SNP and a nearby CpG represent an meQTL pair,
i.e., where the SNP exerts direct influence on the CpG
methylation levels, and thus violates the independence
assumption. While this is less of a problem for PoO×Me
interactions, we show how control triads can be used to
resolve this issue for G×Me analyses.
We showcase our methods on orofacial clefts (OFC),
which are relatively common congenital malformations
with a high heritability and recurrence risk [19]. Several
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GWASes on OFC have been published, confirming pre-
viously reported genes and loci for OFC and identifying
new ones for further investigation (for a review, see [20]).
Besides the genetic variants, environmental factors have
been shown to influence the risk of OFC [21, 22]. A
recent study using Mendelian randomization showed that
DNAmmight mediate genetic liability to clefting [23] and
suggested that the causal pathway might proceed in the
following direction: environment → DNAm → OFC.
In our proof-of-concept analyses described here, we ana-
lyzed a well-vetted set of genetic variants known to be
strongly associated with OFC risk [24]. This increases the
chance of identifying any weaknesses in our theory and
minimizes the multiple-testing burden.
Results
Implementation of the methods
As mentioned, the main idea behind our methods is to
treat the level of DNAm as environmental exposure in
the G×E or PoO×E analyses to estimate the change of
RR of a disease, depending on DNAm levels. The work-
flow of the method is presented in Figs. 1 and 2, while
the details of the modeling framework, implementation,
and analyses are presented in the “Methods” section and
in Additional file 2. Below, we give a brief overview of the
implementation.
We start by summarizing the DNAm levels from sev-
eral CpG sites within a specific region located near a
given SNP (see Fig. 1). To ease the biological interpreta-
tion of the results, we focus on three types of genomic
regions: promoter, enhancer, and gene body (for detailed
definitions, see the “Genomic regions” section). Because
the implementation does not depend on region type, the
methods are equally well applicable to, e.g., CpG-rich
regions or single CpG sites.
Next, to create discrete categories of the continuous
DNAm levels, we average the DNAm levels of the CpGs
within each region and divide the individuals into three
equally sized strata, based on whether their average
DNAm level in a specific region is low, medium, or high.
In the “Discussion” section, we show that our method of
summarizing the DNAm levels helps to retain important
information carried by each CpG site and offsets the dis-
advantages of using sparse, chip-based measurements of
DNAm.
For each DNAm stratum, we estimate the RR of
the SNP relative to the trait and then test for trend
and interaction between strata (see Fig. 2 and the
“Implementation details” section). The interpre-
tation of the G×Me analysis is that a statistically
significant change in RR across strata would indi-
cate an interaction. Similarly, for the PoO×Me
analyses, we perform PoO analyses for each stra-
tum and then check for a significant change across
strata.
Application of the methods
To test ourmethods, we apply them to genotype data from
mother–child dyads and genome-wide DNAm data from
the children only. These data are available on controls and
cases. Cases are children diagnosed with OFC and divided
into following subsets: cleft lip only (CLO), cleft lip with
cleft palate (CLP), cleft lip with or without cleft palate
(CL/P), or cleft palate only (CPO). We focus the current
analyses on the subset of SNPs that showed the strongest
associations with OFC risk in a recent study that used the
same genetic dataset as here [24] (Table 1). Depending
on whether there are any CpGs near a SNP that could be
categorized as belonging to one of promoters, enhancers,
or genes (Table 2), we conduct the G×Me and PoO×Me
analyses up to three times for each SNP in the case tri-
ads. We also repeat the analyses on control data to see
if there are any background correlations between SNPs
and DNAm. This would indicate false-positive results
due to, e.g., the presence of meQTLs. In the sections
below, we present the most significant results. All the
p values are provided in Tables S1–S5 and S7–S11 in
Additional File 1.





analysis 1A: search for interaction between
                   SNP1 and summarized DNAm levels
                   from promoter region
 
analysis 1B: search for interaction between 
                   SNP1 and summarized DNAm levels 
                   from gene region
 
analysis 1C: search for interaction between 
                   SNP1 and summarized DNAm levels
                   from enhancer region
 
(3 GxMe calculations and 3 PoOxMe calculations)
analysis 2A: search for interaction between
                   SNP1 and summarized DNAm levels
                   from promoter region
 
analysis 2B: search for interaction between 
                   SNP1 and summarized DNAm levels 
                   from gene region
 
analysis 2C: search for interaction between 
                   SNP1 and summarized DNAm levels
                   from enhancer region
 
(3 GxMe calculations and 3 PoOxMe calculations)
analysis 3A: search for interaction between
                   SNP1 and summarized DNAm levels
                   from promoter region
 
analysis 3B: search for interaction between 
                   SNP1 and summarized DNAm levels
                   from enhancer region
 
(2 GxMe calculations and 2 PoOxMe calculations)
Fig. 1 Scheme of the choice of SNP–methylation pairs used in the analyses presented here. For each SNP (green circle), we detect all the CpGs
within 50 kb and check which of those are in a promoter, gene, or enhancer region. Note that some of the CpGs can be part of more than one region
type, while some have no annotation. Next, we summarize the DNAm values of all CpGs within each region and use this single value to create strata
and search for gene–methylation (G×Me) or parent-of-origin–methylation (PoO×Me) interaction. For each SNP, we perform six analyses at most
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Fig. 2 Flowchart of the method for integrating DNA methylation information into genetic association analyses. RR relative risk, G×Me
gene–methylation interaction, PoO×Me parent-of-origin–methylation interaction
G×Me analyses
The results of the G×Me analyses are easiest to evalu-
ate when the Wald interaction test p values are plotted
as quantile–quantile (Q-Q) plots (Fig. 3). The Q-Q plots
for CLO and CPO showed no significant interactions.
The results for CL/P pointed to a possible interaction
between rs12543318 at 8q21.3 and the methylation state
of the promoter-flanking region nearby (one CpG, reg-
ulatory stable ID: ENSR00001432551 for GRCh37 and
ENSR00000861245 for GRCh38). The p value of 0.012
indicates a change in the relative risk depending on the
methylation status in that region. Figure 4a also shows
that the risk of CL/P changes markedly among individu-
als carrying at least one C-allele at rs12543318 and whose
Table 1 The SNPs selected for the current analyses, along with the names of the nearest genes (if any), and the measures of
association (relative risks (RR), 95% confidence intervals (CI), and p values; taken from Tables 1–3 in Ref. [24])
SNP Locus Minor allelea MAFa RR 95% CI p value Cleft subtypeb
rs12543318 8q21.3 c 0.31 1.51 1.31–1.75 4.46e−8 CLO
rs987525 8q24 a 0.19 1.85 1.63–2.10 1.47e−19 CLP
rs560426 ABCA4 g 0.44 1.24 1.10–1.41 3.91e−4 CLP
rs3758249 FOXE1 t 0.36 0.78 0.69–0.88 8.18e−5 CLP
rs642961 IRF6 a 0.23 1.60 1.36–1.87 1.41e−8 CLO
rs7078160 KIAA1598 a 0.17 1.33 1.15–1.53 1.04e−4 CLP
rs13041247 MAFB c 0.41 0.67 0.59–0.76 2.32e−9 CLP
rs227731 NOG1 g 0.47 0.74 0.64–0.85 3.8e−5 CPO
rs742071 PAX7 t 0.38 1.52 1.31–1.75 3.74e−8 CLO
rs8001641 SPRY2 g 0.54 0.79 0.70–0.90 2.05e−4 CLP
rs7590268 THADA g 0.25 1.27 1.12–1.46 3.96e−4 CLP
rs1873147 TPM1 g 0.27 1.31 1.13–1.53 5.82e−4 CLO
aThe minor allele and its frequency (MAF) for the Norwegian population were taken from Table 1 in the Appendix of Ref. [24]
bThe cleft subtype (CLO, CPO, or CLP) for which the association was the strongest
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Table 2 Availability of data for G×Me and PoO×Me analyses. We
used genotypes and DNA methylation data and classified CpGs
into one of gene, promoter, or enhancer classes. In each of those
groups, we performed both G×Me and PoO×Me analyses,
where at least one CpG was localized within 50 kb from the
indicated SNP (gray shading; the number indicates how many
CpGs were in each category)
SNP (gene/locus) Enhancer Promoter Gene body
rs12543318 (8q21.3) 1
rs987525 (8q24) 1 1
rs560426 (ABCA4) 6 1 16
rs3758249 (FOXE1) 6 7
rs642961 (IRF6) 14 27
rs7078160 (KIAA1598) 1 1
rs13041247 (MAFB) 21 9
rs227731 (NOG1) 2
rs742071 (PAX7) 1 19 54
rs8001641 (SPRY2) 1 1
rs7590268 (THADA) 1 1 14
rs1873147 (TPM1) 30 29
methylation status at the CpG in question was in the mid-
dle stratum (i.e., between 0.971 and 0.975). This group
had a higher risk of CL/P when the methylation level was
taken into account (i.e., in the stratum “2” in Fig. 4a) versus
when methylation level was not considered (no stratifica-
tion, results for “all” in Fig. 4a). Thus, it is plausible that
the interaction is driven by the change in RR in the middle
stratum. As illustrated in Fig. 4b, the result of the strati-
fied analysis of the control dataset did not show any trend
and was not significant.
The CLP analysis resulted in one significant interaction
between rs3758249 in FOXE1 and the methylation status
of the gene region (Fig. 3, a p value of 0.001). Intriguingly,
we found the same significant interaction in the control
dataset, and the pattern was similar in the analyses of
cases and controls (Fig. 5). Therefore, this interaction is
most likely a false positive. The results of G×Me analysis
on the control dataset produced another significant inter-
action, between rs1873147 in TPM1 and the methylation
status of a promoter region nearby (see Fig. S9 in Addi-
tional File 1). This was not replicated in any of the case
datasets, which could be in part due to sample-size issues
(the control dataset is approximately 3 times larger than
the case datasets).
Random-SNP analysis We checked whether the
assumptions of the G×E modeling framework are met
when using DNAm data as exposure by randomly picking
20 SNPs from the CL/P data (Table S6 in Additional
File 1). We then applied the G×Me procedure on this
dataset to see if there were any false-positive results. As
expected, these analyses did not produce any significant
p values (Fig. 6).
PoO×Me analyses
There were a few borderline significant PoO×Me effects
in the CLO, CLP, and CL/P datasets (Fig. 7). The most
interesting result was the interaction between the PoO
effect of the allele at rs227731, located nearNOG1, and the
methylation status of the promoter-flanking region nearby
(ensembl regulatory ID ENSR00001131154 for version
GRCh37 and ENSR00000559290 for version GRCh38). It
is one of the most significant results among the CL/P, CLP,
and CLO datasets (Fig. 7). The results displayed in Fig. 8
showed that the risk of CL/P was altered among individ-
uals who had inherited at least one G-allele at rs227731
from the mother and in whom the methylation level in
the promoter-flanking region was in the stratum “2” (i.e.,
average β values between 0.51 and 0.52). This group had a
higher risk of CL/P compared to the results of the analy-
sis without stratification (the “all” group). Similar patterns
were observed for CLO and CLP (Figs. S11a and S12b in
Additional File 1).
PoO scan We also conducted a scan over all the SNPs
in the CLP dataset to search for any significant PoO
effects. The top 20 hits from the scan had PoO p values
in the range 2.1 · 10−3 to 0.27 (see Table S12 in Addi-
tional File 1). We then performed PoO×Me analyses on
these top 20 hits in both the CLP and the control datasets
(Fig. 9). Only one SNP had a more significant p value
than would be expected by chance. Namely, the p value
for the interaction between the PoO effect of rs766325
and the methylation level in the promoter region nearby
was above the 95% point-wise confidence interval. The
RR increased with increasing methylation level of the pro-
moter (ensembl regulatory stable ID ENSR00000923082)
(see Fig. S13 in Additional File 1).
Discussion
We present here two methods that incorporate DNAm
data into genetic association analyses, which we call
G×Me and PoO×Me. Although a simpler implemen-
tation of the method for G×Me has previously been
reported [8], our setup is substantially more comprehen-
sive in scope. We also designed a novel PoO×Me analysis
that requires fewer assumptions than G×Me. We applied
the two methods on genotype and DNAm data from chil-
dren with OFC and their mothers, as well as from control
children and their mothers. Both methods are designed
and implemented to facilitate a full genome-wide screen-
ing, but for illustration, we conducted a more targeted
analysis where we focused on a set of SNPs that had previ-
ously shown significant associations with OFC risk. Thus,
any change in the relative risk estimate due to the DNAm
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Fig. 3 Quantile–quantile plots of the interaction p values from the G×Me analyses. The dashed lines represent the 95% confidence interval
level should be easily detectable. Note that when judging
the significance of the results after running our methods
in a full genome scan mode, one can apply any standard
multiple-testing method, typically based on controlling
the false-discovery rate. This is because both methods
return one p value per SNP; we do not consider SNP×SNP
interactions, which would produce a large number of
correlated test results.
There are many ways of combining genetic and methy-
lation data to predict disease prevalence or risk. For
example, Shah et al. [25] tested several linear models to
investigate the extent to which disease prevalence was
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Fig. 4 G×Me effect between rs12543318 at locus 8q21.3 and the methylation level of the CpG from the promoter region nearby. The x-axis groups
the results into the unstratified dataset “all” and the results for each stratum: “1” denoting low methylation level, “2”—medium, and “3”—high
methylation level. The minor and reference alleles are given for each group, along with their frequencies. The y-axis shows the relative risk on a log
scale, with “c” denoting the child effect when only one minor allele is inherited (single dose) and “cdd” denoting the child effect when two such
alleles are inherited (double dose)
due to genetic or methylation components alone. Fur-
ther, White et al. [26] performed a multi-step analysis of
several omics data to identify genetic associations with
neurological disorders. In another work, linear regression
models were tested to identify associations between DNA
methylation levels at specific CpG sites and child’s birth
weight [27]. These results were subsequently used to test
for association between the top CpGs and genotypes. A
few studies searched for an association between a specific
genotype and DNAm at a chosen CpG from a neighboring
region [28–30]. Another study adopted a more integrative
approach by utilizing all the available genetic andmethyla-
tion data to search for differentially methylated CpG sites
and meQTLs associated with breast cancer [31].
In contrast to the research mentioned above, our meth-
ods focus on dyad- or triad-based data, which are robust
study designs that are particularly well-suited for early-
onset disorders where biospecimens can be collected from
both parents and their offspring. Moreover, we use CpG
regions, and not only single CpG sites, to perform region-
based CpG analyses to capture biologically relevant effects
of DNAm on genotype. We implemented our new meth-
ods in the well-established R package Haplin. Our entire
code is available to other researchers interested in testing
and adapting the interaction models to their analyses (see
the “Availability of data and materials” section below).
Summarizing the methylation patterns in regions
facilitates the biological interpretation of results
We assessed the DNAm level of CpG regions instead of
single CpGs and used the most straightforward method to
average the β values from all the CpG sites within a region.
Fig. 5 G×Me effect between rs3758249 in FOXE1 and the methylation level at the CpGs from the gene region. The x-axis groups the results into the
unstratified dataset “all” and the results for each stratum: “1” denoting low methylation level, “2” —medium, and “3” — high methylation level. The
minor and reference alleles are given for each group, along with their frequencies. The y-axis shows the relative risk on a log scale, with “c” denoting
the child effect when only one minor allele is inherited (single dose) and “cdd” denoting the child effect when two such alleles are inherited (double
dose)
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Fig. 6 Quantile–quantile plot of the G×Me results from the analysis
of 20 randomly selected SNPs in the CL/P dataset
This single value from each region was then used to divide
the study participants into equally sized groups accord-
ing to the methylation level of each region. Although each
CpG can have its unique methylation status, methylation
levels of nearby CpGs have been shown to be correlated
[15, 32]. Moreover, averaging the methylation level over
a region has previously been successfully used to search
for differentially methylated regions (DMRs) [33], when
imputing missing values [34], or when defining a methyla-
tion score for a region [35]. If a given CpG displays a much
wider range of methylation levels than other CpGs within
the same region, this CpG will have the largest influence
on the average methylation value.
However, the strategy of summarizing the methylation
pattern in a region has one important caveat. For instance,
let us assume that there are only two CpGs in a given
region, and that, for two individuals, the β values at these
CpG sites are 0.75 and 0.25, and 0.25 and 0.75, respec-
tively. Then these two individuals would be placed in
the same methylation category because the sum is 1 in
both instances.We observed such a phenomenon with the
most significant result of the PoO×Me analyses; namely,
the interaction between rs227731 and DNAm levels of the
promoter region nearby. There were only two CpGs in
this region, and both had narrow and opposite β value
ranges (see Fig. S3). To check whether this was problem-
atic for our methods, we plotted the β values for each
individual at each of the CpG sites separately (Fig. S14
in Additional File 1). The plots showed that there was
still differential grouping of the individuals into strata,
with both of the CpGs exhibiting a wide range of values
across all the strata. We then ran the PoO×Me analyses
only for rs227731 and took only the β values of one of
the promoter-CpGs, i.e., ch.17.52148184R. Table S13 and
Fig. S15 show that the results did not change appreciably
when we excluded one CpG. Notably, the influence of the
methylation values on RR was the same (compared with
Figs. 8, S11a, and S12b), whereas the p values were slightly
higher.
Thus, averaging the methylation level of CpGs appears
to be effective at summarizing the methylation level in
the context of the analyses presented here. In future
work, we will investigate the impact of different parame-
ter choices and assumptions on our methods and explore
how the results might be influenced by the use of a
different methylation-summarizing method. Importantly,
our implementation of the new methods makes them
easily applicable to any other methylation-summarizing
method, also concerning other genomic regions.
We chose 50 kb as the maximum distance from a given
SNP to define the “nearby CpG sites” and to incorporate
the promoter and gene regions in the search. Enhancers,
in particular, are known to exert their effects across long
distances, but the majority of enhancer–gene pairs are
still located within 50 kb [36, 37]. In future develop-
ments of the methods, we will perform a more exhaustive
sensitivity analysis of those parameters.
Our choice of CpGs was guided by the desire to explain
the results in a biologically meaningful context. DNA
methylation controls gene expression by allowing or pre-
venting specific transcription factors to bind to promot-
ers, enhancers, or gene bodies depending on the biological
context [3, 4, 32, 38], which is why we specifically selected
these three regions for our analyses here. Anastasiadi et
al. [17] investigated changes in gene expression that are
associated with changes in the range of DNAm within
promoters, gene bodies, and gene body sub-regions. Their
results indicated that, when the association is significant,
one can use the mean or median value of methylation
instead of the entire set of DNAm values. As a gene body
may span a large region, it may potentially house so-called
cryptic promoters (see, e.g., Ref.[6]), which can regulate
the expression of other genes when their methylation
status changes. Therefore, taking into account all CpGs
within a gene region might lead to increased statistical
power.
Summarizing the methylation patterns in regions may
overcome the disadvantages of using data from a standard
chip
Because our analyses are based on DNAm data from
a microarray chip, we do not have data on all CpG
sites within each of the regions considered. However,
reassuringly, recent extensive genome-wide analyses of
DNAmdata suggest that chip-basedmethodsmay provide
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Fig. 7 Quantile–quantile plots of the interaction p values from the PoO×Me analyses. The dashed lines represent the 95% confidence interval
almost as much information as sequencing techniques
[39]. Another potential problem when using chip-based
DNAm data is the so-called gaps. As shown by Andrews
et al. [40], the measured signals can sometimes be
attributed not to the methylation itself, but, instead, to
a mismatch occurring when a SNP is located within the
DNA sequence of the probe. In those cases, plotting the
β values of one CpG probe for all individuals would
produce a multimodal distribution, typically with gaps
in the plot. Note that while the standard pre-processing
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Fig. 8 PoO×Me interaction between a parent-of-origin effect of rs227731 in NOG1 and the methylation level of the CpGs within a promoter region
nearby. The x-axis groups the results into the unstratified dataset “all” and the results for each stratum: “1” denoting low methylation level, “2” —
medium, and “3” — high methylation level. The minor and reference alleles are given for each group, along with their frequencies. The y-axis shows
the relative risk on a log scale, with “cm_cf” denoting the parent-of-origin effect when only one minor allele is inherited (single dose) and “cdd”
denoting the parent-of-origin effect when two such alleles are inherited (double dose)
procedures include removing the probes with a SNP
within the sequence, each specific dataset might have its
own specific SNPs. We checked for such problems in our
datasets, as described in Additional File 1, Section S2.2.
Thegaphunter algorithm identified two probes as being
possibly problematic. However, we did not find any cor-
relation between the alleles and methylation levels. The
impact of this problem is likely to be negligible on our
methods because we took into account not only single
CpG sites but summarized the methylation level within a
region. Therefore, we chose to retain the data from these
probes.
Control data are helpful in identifying false positives.
Using log-linear models to estimate G×E and even
PoO×E effects from dyad and triad studies has been
thoroughly tested. Our implementation has been shown
to control for the type I error rate satisfactorily even
when moderate sample sizes are used [10]. As long as
the environmental exposure E is exogenous, it is rea-
sonable to assume that the child’s genes and the envi-
ronment are independent of each other, conditional
on parental genotypes. However, as described in the
“Methods” section (“Statistical methods” section and
Additional File 2), it would still be prudent to ask whether
the corresponding conditions (5 and S.7) are satisfied
when treating DNAmas exposure. As a simple and general
test of the validity of our approach, we ran the full CpG
selection strategy and G×Me analyses on 20 randomly
chosen SNPs. This resulted in no false positives, indicat-
ing that the CpG selection procedure did not violate the
assumption of conditional independence.
As an additional test for identifying false positives
among the results for the SNPs in Table 1, we repeated
Fig. 9 Quantile–quantile plot of the p values from the PoO×Me analysis using the top 20 SNPs with the lowest p values from the GWAS scan for
PoO effects of the CLP dataset. The dashed lines represent the 95% confidence interval
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Fig. 10 Histograms of the averaged β values in the CL/P dataset; the red line indicates the median value
these analyses on the same SNPs in the control dataset.
Intriguingly, the results of G×Me in the control dataset
showed a significant interaction between rs3758249 in
FOXE1 and DNAm level in the promoter region nearby,
which was also found to be significant in the analysis of
the CLP dataset. We also repeated this search for inter-
action within the control dataset after having removed
one CpG that was found in the mQTL database [41], i.e.,
cg13791254 (results not shown). The resulting p value
of the Wald test for interaction between rs3758249 in
FOXE1 and the remaining CpGs in the promoter region
was 6.4 · 10−5, which is only a modest change from the
original value 8.6 · 10−5.
This highlights the importance of including a control
dataset to sift through the initial results and to assess
whether the detected G×Me interactions are genuine.
The reason for observing this interaction might be that it
is not specific for OFC, given that the methylation data
were generated using DNA samples from cord blood, and
not from tissues that are more relevant for clefts (e.g.,
buccal epithelial cells or other craniofacial tissue). Nev-
ertheless, the correlation between DNAm levels in blood
and lip/palate tissues has been reported to be high [42].
The G×Me and PoO×Memethods are highly versatile
Since the main idea behind the new methods is to search
for statistical interaction, the methods can be applied to
a wide range of etiologic scenarios. Our implementation
specifies the input as a pair consisting of a SNP and a
methylation value. However, it is up to the user how these
pairs are created, i.e., whether the methylation level is a
value from one CpG alone or a summarized value from
many contiguous CpGs, whether the CpG is located near
or far away from the SNP, as long as the choice makes
biological sense. Moreover, the methods are, in principle,
applicable to any complex disease or binary trait.
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However, several points need to be addressed. These
methods generally require samples from many individu-
als, since they are used to calculate the interaction effect,
not the main effect (see, e.g., Fig. 2 in our previous work
[10]). Thus, if the disease is highly polygenic, substantially
more samples would be required to achieve reasonable
confidence intervals for the interaction estimates. Our
implementation provides more power per sample due to
the calculation of the trend test and because we use only
one measure of methylation level within a region instead
of analyzing each CpG separately. Moreover, while the
Haplin implementation is valid for dichotomous pheno-
types, it should be possible to perform the search for
interaction effects with software for continuous traits.
Furthermore, in our interaction analyses, we divided the
dataset into three strata. This is perhaps the most reason-
able minimum number of strata required, where one can
apply a trend test and visually assess the changes in RR
across strata. To check how sensitive the results were to
the number of methylation strata, we also used two and
four strata (results not shown). Generally, the four-strata
analyses collapsed due to the low number of observations
in each stratum and the two-strata analysis was too crude
to detect trends. With larger sample sizes, a finer division
than three strata may be used.
The interpretation of the significant gene–methylation
interaction is not straightforward
The results of our G×Me analyses point to an interac-
tion in the CL/P dataset between rs12543318 at 8q21.3
and the methylation state at CpG cg03309455 in the
promoter-flanking region nearby (regulatory stable ID:
ENSR00001432551 for GRCh37 and ENSR00000861245
for GRCh38). However, it is not easy to interpret the
biological relevance of this interaction. According to
the JASPAR database [43], two transcription factors
(TFs) are predicted to bind to the sequence contain-
ing CpG cg03309455: ETS-related gene (ERG; uniprot
ID: P11308) and Neurogenic differentiation factor 2
(NEUROD2; uniprot ID: Q15784). While ERG is a gen-
eral factor expressed in 197 tissue types, according to
a search in the bgee database (https://bgee.org/?page=
gene&gene_id=ENSG00000157554), NEUROD2 is specif-
ically involved in neuronal determination. rs12543318
itself is located in a non-coding region, with no genomic
annotation.
As seen in Fig. 4, the above interaction was found in
the CL/P dataset, and there is no matching result in the
control dataset. This raises the probability that the inter-
action is a true positive. However, it should be noted that
across the individuals in our dataset, the range of β val-
ues for this CpG is narrow and higher than 0.95 (Fig. 10a).
Hence, this small absolute difference in methylation value
across the three methylation strata in the interaction
analysis renders a consistent biological interpretation
less likely.
Parent-of-origin effect interaction with DNAmethylation
was significant near rs227731
There was one significant PoO×Me interaction in three of
the five tested datasets, namely, the PoO effect of rs227731
interacting with the methylation values of the promoter
region nearby. There were two CpGs in this region in
our data: ch.17.52148184R and cg24806663. According
to the newest data in the JASPAR database, there are
19 TFs that most probably bind to the cytosine that is
methylated in ch.17.52148184R (Table S14 in Additional
File 1). We checked the gene ontology (GO) annotations
of these proteins in the QuickGO browser (https://www.
ebi.ac.uk/QuickGO/). Of these 19 TFs, 11 were anno-
tated with “multicellular organism development” (GO ID
GO:0007275), while six TFs were annotated with “embry-
onic skeletal system morphogenesis” (GO:0048704). Of
note, one of the TFs is Homeobox protein BarH-like 1
(BARX1, UniprotID: Q9HBU1), which is involved in cran-
iofacial development and odontogenesis [44]. The JAS-
PAR database pointed to only four TFs that most likely
bind to the cytosine in cg24806663 (Table S15 in Addi-
tional File 1), three of which are involved in transcriptional
repression.
At the same time, Fig. 8a shows that this interaction is
due to a noticeable change in the parent-of-origin-specific
relative risk among the individuals within the middle stra-
tum of the DNAm levels. However, since we have β values
that come from chip measurements, it might be that they
do not adequately capture the PoO-specific methylation
distribution among the cell types and DNA strands.
The new PoO×Memethod is robust and can point to
possible imprinting issues
The PoO×Me method presented here has a more
relaxed requirement on the independence between
methylation levels and genotype, as outlined below (the
“Statistical methods” subsection of the “Methods”
section). Furthermore, it makes full use of the dyad and
triad designs. As we have shown previously [45], there are
some advantages of using the dyad design instead of the
full triads, as dyads sometimes provide higher statistical
power relative to the number of genotyped individuals.
However, since the measured β values represent an aver-
age of DNAm levels from several cell types and, impor-
tantly, an average from the two DNA strands, some issues
may remain. One is whether we can correctly capture the
interaction between PoO and the averaged methylation
level; that is, how sensitive is the PoO effect in relation to
methylation? A recent study detailing DNA methylome
dynamics in early embryonic development [46] showed
that the father’s DNAm pattern may be very different
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from the mother’s during this early development. Only a
few genes were found whose expression patterns matched
the DNAm differences. It is thus likely that DNAm alone
cannot induce significant changes in expression, but is
rather associated with variation in gene expression [47].
Our approach to studying PoO×Me effects is closely
related to the contribution of methylation to imprinting.
An imprinted locus can be seen as a locus where methyla-
tion levels in the child may depend on the parent of origin
of the DNA strand. This may potentially lead to an up- or
downregulation of the expression of alleles on that strand
in a PoO-specific manner. There are many approaches
to identify genes that exhibit imprinting [48]. For exam-
ple, a recent study analyzed combinations of DNAm and
genotypes in the child from mother–child dyads [49].
The authors first used maternal genotypes to establish
the parent-of-origin status of SNP alleles in the child’s
DNA and then searched for SNPs that are associated with
methylation status of nearby CpG sites in a parent-of-
origin-specific manner. In our notation, this corresponds
to finding loci where
P(Me|Cij) = P(Me|Cji),
that is, where the distribution of methylation values at
the relevant CpG depends not only on the SNP alleles
themselves but also on which parent they were inherited
from. Interestingly, this is closely related to our assump-
tion (5) (see the “Statistical methods” subsection of the
“Methods” section), which we use to exclude possible false
positives by checking the condition in control families.
While the approach of Cuellar Partida et al. [49] is not
related to a specific phenotype, our analyses are focused
on OFC. We thus look for parent-of-origin-specific corre-
lations between the methylation level (Me) and the child’s
genotype (C) that are present among case-children but not
among control-children.
Conclusions
This study implemented two new strategies to search for
interactions between DNAm levels and either the geno-
type (G×Me) or parent-of-origin (PoO×Me) effects. In
addition, we demonstrate the use of region-wise methyla-
tion levels by focusing on biologicallymeaningful genomic
regions (promoter, gene body, and enhancer). The inclu-
sion of these methods in our R package Haplin facilitates
the ease-of-use and adaptation, as the code is open-source
and free. Additionally, we performed several sensitivity
analyses to test the robustness of our methods. While the
triad and dyad designs allow all of the analyses presented
here to be performed, we note that independent control
triads or dyads are important to check and correct for
false-positive results, particularly for the G×Me model.
Methods
Genotypes
Genotypes from child–mother dyads were available for
cases (1311 dyads) and controls (2481 dyads). Details
regarding data collection and quality checks have been
provided in our previous work [24] and are summa-
rized in Additional File 1. In the case dyads, the child
was diagnosed with one of the following three subtypes
of OFC: cleft lip only (CLO), cleft lip with cleft palate
(CLP), or cleft palate only (CPO). In addition to these,
we also analyzed another category of cleft—cleft lip with
or without cleft palate (CL/P), which is a combination
of CLO and CLP. For the current analyses, we use a
subset of the original dataset by selecting only those
families for whom DNAm data were also available for
the child.
DNAm data
The Illumina HumanMethylation 450K BeadChip (Illu-
mina, Inc., San Diego, CA) was used to assess DNAm
levels at 485,577 CpG sites in the children from the dyads
mentioned above. Details on how the raw data were pro-
cessed are available in our recent work [50] and are sum-
marized in Additional File 1. The β value corresponding
to the methylation level at each CpG site was calculated
as β = IM/(IM + IU + 100), where IU and IM are the
intensities of the unmethylated and methylated signals,
respectively, and the factor 100 is added to ensure no
division by zero. After the quality control, 407,513 CpGs
and 868 samples (456 controls; 105 CLO; 167 CLP and
140 CPO) remained for analysis. Matching of the chil-
dren from the methylation dataset to the genotype dataset
yielded 103 CLO dyads, 269 CL/P dyads, 140 CPO dyads,
166 CLP dyads, and 456 control dyads.
To inspect the entire methylation data and check for
inconsistencies, we (i) performed a statistical summary
of methylation levels in the regulatory regions (promoter,
enhancer, gene body) and (ii) displayed the distributions
of the methylation levels around the chosen SNPs. More
extensive details on these analyses are provided in Addi-
tional File 1 (see Sections S2.1, S2.2, and S2.3). Overall,
the distribution of the methylation levels in our data was
consistent with that of other published datasets [51].
Genomic regions
CpG sites located within a maximum distance of 50 kb
from each SNP were selected and categorized into spe-
cific regions (promoter, enhancer, gene body) using the
newest information from the ensembl database [52]. The
R package biomaRt [53] was used to extract information
from the ensembl Regulatory Feature database (using
GRCh37), which includes the positions of promoters and
enhancers in the human genome. Based on this informa-
tion, we classified a CpG into the category “promoter”
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when the search returned “promoter” (Sequence
Ontology [54] accession number SO:0000167) or “pro-
moter_flanking_region” (SO:0001952). The category
“enhancer” corresponded to the “enhancer” descrip-
tion (SO:0000165). Gene regions were derived from
the ensembl genome browser (GRCh 37) via biomaRt.
Because the positions of the CpGs and SNPs in our raw
data were based on the human genome hg19/GRCh37
release, we did not use the newest version of the human
genome assembly (hg38/GRCh38) to avoid discrepancies
in positional information.
To summarize the DNAm levels per region, we averaged
the β values from the CpG sites within each regulatory
region. Figure 10 presents the distributions of these sum-
marized DNAm levels (Me) per region for the largest
dataset (CL/P). Almost all of the Me distributions have
a normal-like shape, except for the promoter region near
rs987525. The distributions within the other datasets are
presented in Figs. S5–S8 in Additional File 1.
Implementation details
Weused our R package Haplin [10, 55] to calculate relative
risks with confidence intervals for each SNP and for each
cleft category using a log-linear model (haplinStrat
function). The significance of interactions was estimated
using the Wald test (gxe function). Assuming a dose–
response relationship across strata, we also tested for
a trend to increase power. This approach has been
described elsewhere [56]. The scan for PoO effects was
performed using the haplinSlide function, with the
“window size” parameter set to 1. The R code used for the
current analyses is available on the Bitbucket server (see
the “Availability of data and materials” section).
We use the multiplicative scale rather than the additive
scale when assessing interactions. This decision is partly
dictated by the relative risk being the measure of choice
for case-parent triads [55, 57]. Moreover, if significant
interactions are detected on a multiplicative scale, they
will, typically, also be significant on an additive scale; in
that respect, our results are conservative.
We used the R packages ggplot2 [58] and ggrepel [59]
and the ensembl browser (http://www.ensembl.org) to
create the plots. The schemes (Figs. 1 and 2) were cre-
ated using the yEd software (https://www.yworks.com/
products/yed).
Statistical methods
The full framework behind the new methods is presented
in Additional File 2. Here, we highlight the most salient
details.
G×Me interactions
LetM, F, andC denote the genotypes of themother, father,
and child, respectively, within a family triad. Here, M, F,
and C will refer to a single SNP, but could also refer to, for
instance, haplotypes built from a few SNPs in close link-
age disequilibrium. In particular, let Cij = AiAj denote an
ordered child genotype, where allele Ai is inherited from
the mother and Aj from the father. C denotes the corre-
sponding unordered genotype. LetD denote that the child
has the disease in question and D̄ that the child is healthy.
Let Me denote methylation levels in the child, which may
here be low,medium, or high, as described above.We refer
to the families where Me = m as belonging to stratum m.
The penetrance function is P(D|Cij,Me), which describes
how the probability of disease depends on the child’s geno-
type as well as the level of methylation. The penetrance
may depend on parent of origin since P(D|Cij,Me) may
differ from P(D|Cji,Me). Specifically, we assume that
P(D|Cij,Me = m) = B(m) · RR(m)M,i · RR(m)F ,j , (1)
where B(m) is a baseline risk in stratum m, RR(m)M,i is the
relative risk associated with inheriting allele Ai from the
mother in stratum m, and similarly RR(m)F ,j is the relative
risk associated with inheriting allele Aj from the father
in stratum m. We thus assume a multiplicative dose–
response model for the allele dose. To make parameters
identifiable, we assume RR(m)M,1 = RR(m)F ,1 = 1 for all m, i.e.,
we choose A1 as the reference allele in all strata; RR(m)M,i
and RR(m)F ,i should be estimated from the model when
i = 1. More details on models that allow deviations from
the multiplicative dose–response can be found elsewhere
[55, 60].
To look for G×Me effects, we first assume that RR(m)M,i
and RR(m)F ,i are equal for all i and m, i.e., that the risk does
not depend on the parent of origin, and let
RR(m)i = RR(m)M,i = RR(m)F ,i .
A G×Me effect on the risk of disease would mean that the
relative risk RR(m)i changes over strata of Me = m for one
or more i’s.
If data have been sampled as case-parent triads and
control-parent triads, we only observe the distributions
P(M, F ,C,Me|D) and P(M, F ,C,Me|D̄), that is, the joint
distributions of triad genotypes and methylation strata
among the case-parent triads and control-parent triads
separately. The number of triads in each category of geno-
types and methylation strata is modeled as a log-linear
model, and the model parameters are estimated through
maximum likelihood [55, 60]. Since for the case triads,
P(M, F ,C,Me|D)
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there is a direct relationship between the parameters in
the log-linear model and the penetrance model. However,
the model also includes the population parental geno-
type distribution P(M, F), the straightforward Mendelian
transmission part P(C|M, F), and the population disease
prevalence P(D). The latter may not be known, but enters
the model as a scaling factor.
The basic case-parent and control-parent triad mod-
els are formulated in terms of child and both parents.
However, the Haplin implementation allows mother–
child and father–child dyads to be fitted within the same
framework. This is achieved by using the expectation-
maximization (EM) algorithm to impute the missing par-
ent and basing inference on the likelihood that accounts
for missing data. Further details on how the log-linear
models is implemented can be found elsewhere [55, 56].
The factor P(Me|M, F ,C), i.e., the population distribu-
tion of methylation within genetic strata, is crucial in our
analyses. When independent control triads are available,
we make an assumption—for simplicity—of rare disease.
In that case,
P(M, F ,C,Me|D̄) ≈ P(Me|M, F ,C)P(C|M, F)P(M, F).
(3)
Thus, when controls are available, there is no need to
make specific assumptions about P(Me|M, F ,C) since it
can be estimated from control triads. With only case-
parent triads available, however, it is clear that assump-
tions about P(Me|M, F ,C)may interfere with inference on
P(D|M, F ,C,Me) when observing P(M, F ,C,Me|D) only.
In Additional File 2, we present the details on the most
important situations where this becomes relevant.
PoO×Me effects
PoO effects have been described in different ways in the
literature—here, we measure it as a ratio of relative risks
(RRR). Specifically, if RRM and RRF are the relative risks
associated with the maternally and paternally derived alle-
les, respectively, then the PoO effect within a stratum is
RRR = RRM/RRF . See Gjerdevik et al. [10] for further
details on the PoO definition.
To estimate parent-of-origin effects, we now assume
that RRM,i is not necessarily equal to RRF ,i. In other words,
the effect of allele Ai on offspring risk may depend on
the parental source of the allele. Let RRRi = RRM,i/RRF ,i
be the ratio of the relative risks associated with allele Ai.
Thus, RRRi = 1 is indicative of a parent-of-origin effect.
Let RRR(m)i be the value of RRRi estimated in stratum
Me = m, and Cij as defined above. As above, we assume
P(D|M, F ,Cij,Me) = P(D|Cij,Me). To be able to estimate
the ratio RRR(m)i within each stratum, we again need to
make an assumption
P(Me|M, F ,C) = P(Me|M, F), (4)
i.e., that the methylation in the child may be associated
with (parental) genotypes in the population, but that the
child’s genotype does not directly influence methylation,
conditional on parental genotypes. However, it will now
suffice to assume that
P(Me|M, F ,Cij) = P(Me|M, F ,Cji) = P(Me|M, F ,C),
(5)
i.e., the child’s genes may influence methylation levels
directly, even within parental mating types, but the mech-
anisms by which the child’s genotype influences methyla-
tion values should not depend on whether specific alleles
were inherited from the mother or from the father. Under
condition (5),
P(M, F ,Cij,Me|D) = P(D|Cij,Me)P(Me|M, F ,Cij)P(M, F ,Cij)P(D)




Note that the last fraction is again determined by standard
Mendelian inheritance. In a stratum-specific log-linear
model, we can still obtain estimates of RR(m)M,i and RR
(m)
F ,i
for each stratum m. These estimates may be biased since
P(C|M, F ,Me) may depend on both Me = m and the
(unordered) C = AiAj. However, the ratio RRR(m)i =
RR(m)M,i/RR
(m)
F ,i will be unbiased as long as condition (5) is
satisfied.
Again, if control triads are available, under the rare dis-
ease assumption, we can use estimates from the control
triads to check the symmetry assumption (5), or in a com-
bined (hybrid) analysis, unbiased estimates of RR(m)M,2 and
RR(m)F ,2 can be obtained.
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